Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adams “edible film” OTCs

This article was originally published in The Tan Sheet

Executive Summary

Adams Respiratory Therapeutics will develop oral thin-film drug delivery OTC and pharmaceutical respiratory products under a licensing agreement with drug delivery firm MonoSol Rx, the company announces March 27. Under the deal, Adams receives an exclusive, royalty-bearing non-transferable license from MonoSol to develop and market two or more respiratory products in North America. Under a separate agreement, MonoSol will manufacture and supply the finished products. MonoSol will complete product development, while Adams will perform all clinical development, regulatory submissions and commercial operations. Financial terms of the deal were not disclosed, but Adams notes MonoSol will receive payments in exchange for completing pre-defined development milestones. Leiner launched several OTC drug and dietary supplement products in orally dissolving strips in 2005 under a deal with MonoSol (1"The Tan Sheet" Aug. 15, 2005, p. 8)...

You may also be interested in...



Leiner, MonoSol Deal Brings Oral Strip Technology To Private Label Market

Leiner will launch at least three new OTC drug and dietary supplement products in orally dissolving strip formulations later this year under a licensing agreement with MonoSol Rx

Q&A: Renalytix AI Prez Explains How MCIT Rule Will Aid Kidney Product Coverage By CMS

Tom McLain tells how the new MCIT policy from the US Medicare agency – and winning support from Congress – will guarantee Medicare coverage for his company’s product, an artificial intelligence-enabled in vitro diagnostic platform.

Bridges Consumer Startup Reaches Brands For Specialty Conditions In Clarion Deal

Acquiring Clarion Brands from Swander Pace, Bridges Consumer Healthcare adds portfolio of OTC and supplement brands for symptoms including tinnitus, urinary pain relief and excessive sweating.

Topics

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel